Rethinking length of stay in patients after cardiac surgery: the role of pharmacist-led medication review
Published
April 15, 2026
Paper ID
PAP-000032
Status
Published
DOI
10.65712/tmj.test000290
Advance Services
Abstract
Background: Earlier studies of pharmacist-led medication review were small or single-centre. Methods: Eligible participants were patients after cardiac surgery. Results: Serious adverse events were rare and similar between groups. length of stay occurred in 16% of the intervention group versus 30% of controls. Conclusion: Future work should test pharmacist-led medication review in a pragmatic multicentre trial.
Introduction
length of stay remains a leading cause of avoidable harm among patients after cardiac surgery. Earlier studies of pharmacist-led medication review were small or single-centre. The cost of length of stay to health systems is substantial. Guidelines make only a weak recommendation on pharmacist-led medication review.
Practice around pharmacist-led medication review varies widely between centres. The cost of length of stay to health systems is substantial. Guidelines make only a weak recommendation on pharmacist-led medication review.
Earlier studies of pharmacist-led medication review were small or single-centre. The cost of length of stay to health systems is substantial. length of stay remains a leading cause of avoidable harm among patients after cardiac surgery.
Materials and Methods
Analyses were adjusted for age, sex and baseline severity. We conducted a cross-sectional survey across 9 centres between 2014 and 2024.
Missing data were handled with multiple imputation. We conducted a cross-sectional survey across 4 centres between 2014 and 2025. We conducted a cross-sectional survey across 2 centres between 2017 and 2022.
The primary outcome was length of stay, assessed blind to allocation. Eligible participants were patients after cardiac surgery.
The primary outcome was length of stay, assessed blind to allocation. We conducted a cross-sectional survey across 2 centres between 2016 and 2024.
Results
length of stay occurred in 18% of the intervention group versus 26% of controls. length of stay occurred in 6% of the intervention group versus 13% of controls. Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.67 (95% CI 0.26 to 0.94).
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Control | 615 | 37 | 30.9 | 0.99 |
| Centre B | 378 | 102 | 22.3 | 0.49 |
| Male | 783 | 36 | 38.8 | 0.61 |
Values are n (%) unless stated otherwise.

Shown for patients after cardiac surgery; error bars are 95% confidence intervals.

Shown for patients after cardiac surgery; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. length of stay occurred in 13% of the intervention group versus 35% of controls. The adjusted odds ratio was 0.52 (95% CI 0.26 to 0.69). Serious adverse events were rare and similar between groups.
1955 participants were included (median age 70 years). The adjusted odds ratio was 0.80 (95% CI 0.35 to 0.98). The adjusted odds ratio was 0.82 (95% CI 0.49 to 0.95).
Discussion
Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment. These findings suggest that pharmacist-led medication review is associated with better length of stay in patients after cardiac surgery.
These findings suggest that pharmacist-led medication review is associated with better length of stay in patients after cardiac surgery. Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.
Implementation will depend on staffing, cost and local protocols. These findings suggest that pharmacist-led medication review is associated with better length of stay in patients after cardiac surgery.
Future work should test pharmacist-led medication review in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.
Strengths include the sample size and blinded outcome assessment. These findings suggest that pharmacist-led medication review is associated with better length of stay in patients after cardiac surgery.
Conclusions
Pharmacist-led medication review should be considered for patients after cardiac surgery to improve length of stay.
References
1. Rossi A, Dubois N, et al. Home-based cardiac rehabilitation and health-related quality of life. N Engl J Med. 2024;27(3):375-1706.
2. Nasser S, Silva S, et al. Prone positioning and emergency department revisits. JAMA. 2023;110(5):49-1348.
3. Kowalski P, Rossi I, et al. Low-dose aspirin and surgical site infection. Diabetes Care. 2010;47(4):757-1432.
4. Mensah O, Kim Z, et al. Point-of-care ultrasound and chronic pain scores. Crit Care Med. 2013;337(9):882-1112.
5. Ibrahim V, Zhang R, et al. A sepsis alert system and length of stay. BMJ. 2016;76(4):258-1334.
6. Zhang J, Okafor N, et al. Low-dose aspirin and patient satisfaction. JAMA. 2008;106(10):586-1669.
7. Larsen U, Kowalski S, et al. SGLT2 inhibitors and patient satisfaction. BMJ. 2016;344(9):480-1118.
Appendices
Supplementary tables are available on request.